COMMUNIQUÉS West-GlobeNewswire

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06/12/2024
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; [...]
GRI Bio to Participate in the Virtual Investor Closing Bell Series
06/12/2024
Live webcast on Thursday, December 12 th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline [...]
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
06/12/2024
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 percent of their [...]
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
06/12/2024
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024
DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
06/12/2024
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06/12/2024
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement [...]
FluidForm Bio™ Announces Participation in the New England Venture Summit
06/12/2024
WALTHAM, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will delivery a company [...]
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
06/12/2024
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
06/12/2024
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary [...]
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
06/12/2024
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to [...]
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
06/12/2024
Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending [...]
Profound Medical Announces Proposed Public Offering of Common Shares
05/12/2024
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: [...]
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
05/12/2024
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by [...]
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
05/12/2024
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today [...]
Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open
05/12/2024
Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:ISRG) The peer-reviewed Annals of Surgery published a meta-analysis of [...]
CooperCompanies Announces Fourth Quarter and Full Year 2024 Results
05/12/2024
SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31 [...]
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
05/12/2024
Underwriters’ full exercise of option brings gross proceeds to $862.5 million REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company [...]

Pages